VYLUMA COMPLETES LAST PATIENT VISIT FOR PRIMARY ANALYSIS OF PIVOTAL PHASE III CHAMP STUDY EVALUATING NVK002 FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN
Multi-center, international clinical study designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia
This link leads to the machine readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of-network allowed amounts between health plans and healthcare providers. The machine-readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data.
https://www.cigna.com/legal/compliance/machine-readable-files